{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T21:59:45Z","timestamp":1775167185418,"version":"3.50.1"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vascular Pharmacology"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.vph.2015.06.009","type":"journal-article","created":{"date-parts":[[2015,6,23]],"date-time":"2015-06-23T04:47:57Z","timestamp":1435034877000},"page":"1-9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":66,"special_numbering":"C","title":["Homocysteine, methylenetetrahydrofolate reductase, folate status and atherothrombosis: A mechanistic and clinical perspective"],"prefix":"10.1016","volume":"78","author":[{"given":"Francesca","family":"Santilli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Dav\u00ec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Patrono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vph.2015.06.009_bb0005","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1056\/NEJM199104253241701","article-title":"Hyperhomocysteinemia: an independent risk factor for vascular disease","volume":"324","author":"Clarke","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vph.2015.06.009_bb0010","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1373\/clinchem.2012.187286","article-title":"Homocysteine and cardiovascular risk: the perils of reductionism in a complex system","volume":"58","author":"Ueland","year":"2012","journal-title":"Clin. Chem."},{"key":"10.1016\/j.vph.2015.06.009_bb0015","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1001\/jama.288.16.2015","article-title":"Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis","volume":"288","author":"Homocysteine Studies Collaboration","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.vph.2015.06.009_bb0020","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1001\/archinternmed.2010.348","article-title":"Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: meta-analysis of 8 randomized trials involving 37 485 individuals","volume":"170","author":"Clarke","year":"2010","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.vph.2015.06.009_bb0025","first-page":"CD006612","article-title":"Homocysteine-lowering interventions for preventing cardiovascular events","volume":"1","author":"Marti-Carvajal","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.vph.2015.06.009_bb0030","first-page":"1","article-title":"The natural history of homocystinuria due to cystathionine beta-synthase deficiency","volume":"37","author":"Mudd","year":"1985","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.vph.2015.06.009_bb0035","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1023\/A:1005445132327","article-title":"Homocysteinemia due to cystathionine \u03b2 synthase deficiency in Ireland: 25years experience of newborn screened and treated population with reference to a clinical outcome and biochemical control","volume":"21","author":"Yap","year":"1998","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.vph.2015.06.009_bb0040","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1161\/hq1201.100225","article-title":"Vascular outcome in patients with homocystinuria due to cystathionine-synthase deficiency treated chronically. A multicenter observational study","volume":"21","author":"Yap","year":"2001","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.vph.2015.06.009_bb0045","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1055\/s-2000-8100","article-title":"Vascular complications of severe hyperhomocysteinemia in patients with homocystinuria due to cystathionine beta-synthase deficiency: effects of homocysteine-lowering therapy","volume":"26","author":"Yap","year":"2000","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.vph.2015.06.009_bb0050","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1136\/bmj.325.7374.1202","article-title":"Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis","volume":"325","author":"Wald","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.vph.2015.06.009_bb0055","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1093\/ajcn\/72.2.324","article-title":"The controversy over homocysteine and cardiovascular risk","volume":"72","author":"Ueland","year":"2000","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.vph.2015.06.009_bb0060","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1093\/ajcn\/81.6.1257","article-title":"The phenomenon of altered risk factor patterns or reverse epidemiology in persons with advanced chronic kidney failure","volume":"81","author":"Kopple","year":"2005","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.vph.2015.06.009_bb0065","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1161\/CIRCULATIONAHA.105.570127","article-title":"Relationship between homocysteine and mortality in chronic kidney disease","volume":"113","author":"Menon","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2015.06.009_bb0070","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1681\/ASN.2004070576","article-title":"Fasting plasma total homocysteine levels and mortality and allograft loss in kidney transplant recipients: a prospective study","volume":"16","author":"Winkelmayer","year":"2005","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.vph.2015.06.009_bb0075","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1001\/jama.298.10.1163","article-title":"Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial","volume":"298","author":"Jamison","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.vph.2015.06.009_bb0080","doi-asserted-by":"crossref","first-page":"e3533","DOI":"10.1136\/bmj.e3533","article-title":"The effect of folic acid based homocysteine lowering on cardiovascular events in people with kidney disease: systematic review and meta-analysis","volume":"344","author":"Jardine","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.vph.2015.06.009_bb0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ije\/dyg070","article-title":"Mendelian randomization: can genetic epidemiology contribute to understanding environmental determinants of disease?","volume":"32","author":"Smith","year":"2003","journal-title":"Int. J. Epidemiol."},{"key":"10.1016\/j.vph.2015.06.009_bb0090","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/ng0595-111","article-title":"A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase","volume":"10","author":"Frosst","year":"1995","journal-title":"Nat. Genet."},{"key":"10.1016\/j.vph.2015.06.009_bb0095","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1161\/01.CIR.98.23.2520","article-title":"Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: the result of a meta-analysis","volume":"98","author":"Brattstrom","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2015.06.009_bb0100","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1161\/01.CIR.93.1.7","article-title":"Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations","volume":"93","author":"Jacques","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2015.06.009_bb0105","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1136\/bmj.38611.658947.55","article-title":"Meta-analysis of MTHFR 677C\u2192T polymorphism and coronary heart disease: does totality of evidence support causal role for homocysteine and preventive potential of folate?","volume":"331","author":"Lewis","year":"2005","journal-title":"BMJ"},{"key":"10.1016\/j.vph.2015.06.009_bb0110","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1001\/jama.288.16.2023","article-title":"MTHFR 677C\u2192T polymorphism and risk of coronary heart disease: a meta-analysis","volume":"288","author":"Klerk","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.vph.2015.06.009_bb0115","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.3945\/ajcn.111.022384","article-title":"Prospective study of methylenetetrahydrofolate reductase (MTHFR) variant C677T and risk of all-cause and cardiovascular disease mortality among 6000 US adults","volume":"95","author":"Yang","year":"2012","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.vph.2015.06.009_bb0120","doi-asserted-by":"crossref","first-page":"e1001177","DOI":"10.1371\/journal.pmed.1001177","article-title":"Homocysteine and coronary heart disease: meta-analysis of MTHFR case\u2013control studies, avoiding publication bias","volume":"9","author":"Clarke","year":"2012","journal-title":"PLoS Med."},{"key":"10.1016\/j.vph.2015.06.009_bb0125","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1373\/clinchem.2012.191791","article-title":"Homocysteine as a cause of ischemic heart disease: the door remains open","volume":"58","author":"Wald","year":"2012","journal-title":"Clin. Chem."},{"key":"10.1016\/j.vph.2015.06.009_bb0130","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/S0140-6736(11)60872-6","article-title":"Effect modification by population dietary folate on the association between MTHFR genotype, homocysteine, and stroke risk: a meta-analysis of genetic studies and randomised trials","volume":"378","author":"Holmes","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.vph.2015.06.009_bb0135","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ymgme.2009.05.012","article-title":"Polygenic association with total homocysteine in the post-folic acid fortification era: the CARDIA study","volume":"98","author":"Tsai","year":"2009","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.vph.2015.06.009_bb0140","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1161\/01.ATV.17.6.1157","article-title":"The effects of folic acid supplementation on plasma total homocysteine are modulated by multivitamin use and methylenetetrahydrofolate reductase genotypes","volume":"17","author":"Malinow","year":"1997","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.vph.2015.06.009_bb0145","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1056\/NEJMoa055227","article-title":"Homocysteine lowering and cardiovascular events after acute myocardial infarction","volume":"354","author":"Bonaa","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vph.2015.06.009_bb0150","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1056\/NEJMoa060900","article-title":"Homocysteine lowering with folic acid and B vitamins in vascular disease","volume":"354","author":"Lonn","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vph.2015.06.009_bb0155","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1001\/jama.291.5.565","article-title":"Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial","volume":"291","author":"Toole","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.vph.2015.06.009_bb0160","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1001\/jama.299.17.2027","article-title":"Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial","volume":"299","author":"Albert","year":"2008","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.vph.2015.06.009_bb0165","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1001\/jama.300.7.795","article-title":"Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: a randomized controlled trial","volume":"300","author":"Ebbing","year":"2008","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.vph.2015.06.009_bb0170","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.2010.840","article-title":"Effects of homocysteine-lowering with folic acid plus vitamin B12 vs placebo on mortality and major morbidity in myocardial infarction survivors: a randomized trial","volume":"303","author":"SEARCH Study Collaborative Group","year":"2010","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.vph.2015.06.009_bb0175","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1056\/NEJMe068060","article-title":"Homocysteine trials-clear outcomes for complex reasons","volume":"354","author":"Loscalzo","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vph.2015.06.009_bb0180","doi-asserted-by":"crossref","first-page":"e16473","DOI":"10.1371\/journal.pone.0016473","article-title":"Reconciling the evidence on serum homocysteine and ischaemic heart disease: a meta-analysis","volume":"6","author":"Wald","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.vph.2015.06.009_bb0185","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1001\/jama.2015.2274","article-title":"Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: the CSPPT randomized clinical trial","volume":"313","author":"Huo","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.vph.2015.06.009_bb0190","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1093\/oxfordjournals.aje.a008798","article-title":"Lowered risks of hypertension and cerebro-vascular disease after vitamin\/mineral supplementation: the Linxian Nutrition Intervention Trial","volume":"143","author":"Mark","year":"1996","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.vph.2015.06.009_bb0200","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1161\/STROKEAHA.108.529503","article-title":"Homocysteine-lowering therapy and stroke risk, severity, and disability: additional findings from the HOPE 2 trial","volume":"40","author":"Saposnik","year":"2009","journal-title":"Stroke"},{"key":"10.1016\/j.vph.2015.06.009_bb0205","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S1474-4422(10)70187-3","article-title":"B vitamins in patients with recent transient ischaemic attack or stroke in the VITAmins TO Prevent Stroke (VITATOPS) trial: a randomised, double-blind, parallel, placebo-controlled trial","volume":"9","author":"VITATOPS Trial Study Group","year":"2010","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.vph.2015.06.009_bb0210","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S1474-4422(12)70091-1","article-title":"Antiplatelet therapy and the effects of B vitamins in patients with previous stroke or transient ischaemic attack: a post-hoc subanalysis of VITATOPS, a randomised, placebo-controlled trial","volume":"11","author":"Hankey","year":"2012","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.vph.2015.06.009_bb0215","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1001\/jama.2015.1961","article-title":"Folate supplements for stroke prevention: targeted trial trumps the rest","volume":"313","author":"Stampfer","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.vph.2015.06.009_bb0220","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1016\/S0140-6736(07)60854-X","article-title":"Efficacy of folic acid supplementation in stroke prevention: a meta-analysis","volume":"369","author":"Wang","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.vph.2015.06.009_bb0225","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1161\/STROKEAHA.110.578906","article-title":"Dietary folate and vitamin B6 and B12 intake in relation to mortality from cardiovascular diseases: Japan collaborative cohort study","volume":"41","author":"Cui","year":"2010","journal-title":"Stroke"},{"key":"10.1016\/j.vph.2015.06.009_bb0230","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/j.1742-1241.2012.02929.x","article-title":"Efficacy of folic acid supplementation in stroke prevention: new insight from a meta-analysis","volume":"66","author":"Huo","year":"2012","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.vph.2015.06.009_bb0235","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/ijs.12017","article-title":"The China Stroke Secondary Prevention Trial (CSSPT) protocol: a double-blinded, randomized, controlled trial of combined folic acid and B vitamins for secondary prevention of stroke","volume":"10","author":"Liu","year":"2015","journal-title":"Int. J. Stroke"},{"key":"10.1016\/j.vph.2015.06.009_bb0240","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1136\/heartjnl-2013-304460","article-title":"The association between plasma homocysteine and coronary heart disease is modified by the MTHFR 677C>T polymorphism","volume":"99","author":"Mehlig","year":"2013","journal-title":"Heart"},{"key":"10.1016\/j.vph.2015.06.009_bb0245","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.3945\/jn.111.157180","article-title":"Folate network genetic variation predicts cardiovascular disease risk in non-Hispanic white males","volume":"142","author":"Wernimont","year":"2012","journal-title":"J. Nutr."},{"key":"10.1016\/j.vph.2015.06.009_bb0250","doi-asserted-by":"crossref","first-page":"e1004214","DOI":"10.1371\/journal.pgen.1004214","article-title":"Genome-wide meta-analysis of homocysteine and methionine metabolism identifies five one carbon metabolism loci and a novel association of ALDH1L1 with ischemic stroke","volume":"10","author":"Williams","year":"2014","journal-title":"PLoS Genet."},{"key":"10.1016\/j.vph.2015.06.009_bb0255","doi-asserted-by":"crossref","first-page":"668","DOI":"10.3945\/ajcn.112.044545","article-title":"Common genetic loci influencing plasma homocysteine concentrations and their effect on risk of coronary artery disease","volume":"98","author":"van Meurs","year":"2013","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.vph.2015.06.009_bb0260","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.atherosclerosis.2013.02.019","article-title":"The potential role of homocysteine mediated DNA methylation and associated epigenetic changes in abdominal aortic aneurysm formation","volume":"228","author":"Krishna","year":"2013","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.vph.2015.06.009_bb0265","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1515\/cclm-2012-0694","article-title":"Folic acid supplementation does not reduce intracellular homocysteine, and may disturb intracellular one-carbon metabolism","volume":"51","author":"Smith","year":"2013","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.vph.2015.06.009_bb0270","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1161\/CIRCULATIONAHA.108.808675","article-title":"MTHFR 677 C>T polymorphism reveals functional importance for 5-methyltetrahydrofolate, not homocysteine, in regulation of vascular redox state and endothelial function in human atherosclerosis","volume":"119","author":"Antoniades","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2015.06.009_bb0275","doi-asserted-by":"crossref","first-page":"E1061","DOI":"10.1152\/ajpendo.00367.2010","article-title":"Homocysteine impairs coronary artery endothelial function by inhibiting tetrahydrobiopterin in patients with hyperhomocysteinemia","volume":"299","author":"He","year":"2010","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.vph.2015.06.009_bb0280","doi-asserted-by":"crossref","first-page":"22546","DOI":"10.1074\/jbc.M302227200","article-title":"Interactions of peroxynitrite, tetrahydrobiopterin, ascorbic acid, and thiols: implications for uncoupling endothelial nitric-oxide synthase","volume":"278","author":"Kuzkaya","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.vph.2015.06.009_bb0285","doi-asserted-by":"crossref","first-page":"E1176","DOI":"10.1152\/ajpendo.00084.2011","article-title":"Role of tetrahydrobiopterin (BH4) in hyperhomocysteinemia-induced endothelial dysfunction: new indication for this orphan-drug?","volume":"300","author":"Kietadisorn","year":"2011","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.vph.2015.06.009_bb0290","first-page":"51","article-title":"Does vitamin C enhance nitric oxide bioavailability in a tetrahydrobiopterin-dependent manner? In vitro, in vivo and clinical studies","volume":"36C","author":"Mortensen","year":"2013","journal-title":"Nitric Oxide"},{"key":"10.1016\/j.vph.2015.06.009_bb0295","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.3390\/nu5083235","article-title":"Methoxistasis: integrating the roles of homocysteine and folic acid in cardiovascular pathobiology","volume":"5","author":"Joseph","year":"2013","journal-title":"Nutrients"},{"key":"10.1016\/j.vph.2015.06.009_bb0300","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1016\/j.jacc.2005.02.053","article-title":"Glutathione peroxidase-1 and homocysteine for cardiovascular risk prediction: results from the AtheroGene study","volume":"45","author":"Schnabel","year":"2005","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.vph.2015.06.009_bb0305","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1089\/ars.2010.3586","article-title":"Glutathione peroxidase-1 in health and disease: from molecular mechanisms to therapeutic opportunities","volume":"15","author":"Lubos","year":"2011","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.vph.2015.06.009_bb0310","doi-asserted-by":"crossref","first-page":"340","DOI":"10.3390\/nu5020340","article-title":"Selenistasis: epistatic effects of selenium on cardiovascular phenotype","volume":"5","author":"Joseph","year":"2013","journal-title":"Nutrients"},{"key":"10.1016\/j.vph.2015.06.009_bb0315","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1161\/hc3501.095287","article-title":"Oxidative stress and platelet activation in homozygous homocystinuria","volume":"104","author":"Dav\u00ec","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2015.06.009_bb0320","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1160\/TH11-12-0899","article-title":"Oxidative stress and platelet activation in subjects with moderate hyperhomocysteinaemia due to MTHFR 677 C\u2192T polymorphism","volume":"108","author":"Dragani","year":"2012","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.vph.2015.06.009_bb0325","doi-asserted-by":"crossref","first-page":"15812","DOI":"10.1073\/pnas.1309049110","article-title":"Hydrogen sulphide pathway contributes to the enhanced human platelet aggregation in hyperhomocysteinemia","volume":"110","author":"d'Emmanuele di Villa Bianca","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.vph.2015.06.009_bb0330","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMra071014","article-title":"Platelet activation and atherothrombosis","volume":"357","author":"Dav\u00ec","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vph.2015.06.009_bb0335","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1172\/JCI118776","article-title":"The oxidant stress of hyperhomocyst(e)inemia","volume":"98","author":"Loscalzo","year":"1996","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.vph.2015.06.009_bb0340","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1161\/01.STR.0000169946.31639.af","article-title":"Dose-related association of MTHFR 677T allele with risk of ischemic stroke: evidence from a cumulative meta-analysis","volume":"36","author":"Cronin","year":"2005","journal-title":"Stroke"},{"key":"10.1016\/j.vph.2015.06.009_bb0345","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1016\/j.thromres.2011.05.017","article-title":"Genotype-independent in vivo oxidative stress following a methionine loading test: maximal platelet activation in subjects with early-onset thrombosis","volume":"128","author":"Di Minno","year":"2011","journal-title":"Thromb. Res."},{"key":"10.1016\/j.vph.2015.06.009_bb0350","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.thromres.2011.10.006","article-title":"Urinary excretion of iPF(2alpha)-III predicts the risk of future thrombotic events. A 10-year follow-up","volume":"129","author":"Di Minno","year":"2012","journal-title":"Thromb. Res."},{"key":"10.1016\/j.vph.2015.06.009_bb0355","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.3945\/ajcn.112.037655","article-title":"Complex relations of genetic polymorphisms with nutritionally influenced biomarkers","volume":"95","author":"Glynn","year":"2012","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.vph.2015.06.009_bb0360","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/1752-0509-7-62","article-title":"A network-based approach for predicting key enzymes explaining metabolite abundance alterations in a disease phenotype","volume":"7","author":"Pey","year":"2013","journal-title":"BMC Syst. Biol."},{"key":"10.1016\/j.vph.2015.06.009_bb0365","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","author":"Antithrombotic Trialists' (ATT) Collaboration","year":"2009","journal-title":"Lancet"}],"container-title":["Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189115001408?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189115001408?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,5,14]],"date-time":"2022-05-14T19:12:58Z","timestamp":1652555578000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1537189115001408"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":72,"alternative-id":["S1537189115001408"],"URL":"https:\/\/doi.org\/10.1016\/j.vph.2015.06.009","relation":{},"ISSN":["1537-1891"],"issn-type":[{"value":"1537-1891","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Homocysteine, methylenetetrahydrofolate reductase, folate status and atherothrombosis: A mechanistic and clinical perspective","name":"articletitle","label":"Article Title"},{"value":"Vascular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vph.2015.06.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}